News

Mind the Byte acquires Intelligent Pharma

Mind the Byte, a pioneer in the development of technologies based on artificial intelligence, cloud and big data for computational drug design, has acquired 100% of Intelligent Pharma, one of the leaders in Spain in chemoinformatics services for the...

CADD validation of meridianins as inhibitors of tau phosphorylation

Mind the Byte scientists have computationally evaluated and reported the inhibitory activity found in meridianins A–G, a group of marine molecules isolated from the tunicate Aplidium, against various protein kinases involved in Alzheimer’s disease (AD)....

Alliance with the Josep Carreras Foundation to fight leukemia

Mind the Byte has created a consortium together with the Josep Carreras Leukemia Research Institute to work on the development of potential treatments for the T-cell acute lymphoblastic leukemia (T- ALL), which is an orphan disease with very poor...

Mind the Byte and Prosilico sign a strategic partnership agreement

Together, the two companies will provide a broad portfolio of in silico models covering most aspects of virtual drug discovery and development. Prosilico software will now be included in Mind the Byte’s SaaS platform and both firms will promote each...

Benefit from Boost4Health programme for your in silico analyses

Mind the Byte helps you to improve drug development. We are a bioinformatics company specialized in computer-aided drug discovery. Our main goal is to help our clients make better, safer and more adequate drugs adjusted to the patient needs, reducing the...

Mind the Byte, member of a consortium to receive 2M

Mind the Byte is one of the partners in the NOAH research program, slated to receive €2 million in funding over the next four years to develop therapies within the area of functional molecular containers, encapsulation processes and their applications, to...